Fluoroscence In Situ Hybridization (FISH) In Chronic Myeloid Leukemia (CML)
Pain Management
Early Stage Hodgkin's Disease
Emergency Medicine And Cardiopulmonary Resuscitation
Non Hodgkin Lymphoma
Management Of Non Metastatic Ewing's Sarcoma

Urological Malignancies
Bone And Soft Tissue Tumors
Carcinomas
Metastatic Breast Cancer
Gastro-Intestinal Cancer

MBBS from L.L.R.M. Medical college, Meerut University, India in 1993
D.C.H. from Lala Lajpat Rai Medical College (LLRM), Meerut University, India in 1995
European School of Medical Oncology accreditation from Barcelona, Spain in 2007
Certificate in Medical Oncology from General Medical Council, UK in 2009

1. Director & Chief Consultant, Medical &Haemato-Oncology (Pan-Max), Max Cancer Centre, Max Healthcare, New Delhi, October 2009 –June 2010
2. Consultant Medical Oncology, Guy’s and St Thomas’ NHS foundation Trust, London
Consultant Medical Oncologist (Haem-Oncology), Parkside Oncology Clinic, Wimbledon. June 2009 –October 2009
3. Consultant Medical Oncology, Addenbrookes hospital, Hills Road, Cambridge, May 2008 – June 2009
4. Department of Medical & Haemato-Oncology, Royal Marsden NHS Foundation Trust, Chelsea and Sutton, London. Feb 1998-May 2008
5. Department of Medical Oncology, Prof S H Advani MD, FICP, Prof Purvish Parikh MD, Medical Oncology / Medicine, Tata Cancer Hospital, Parel, Mumbai, India, Dec 1996-Jan 1998
6. Medical Oncology/ Medicine, Indraprastha Apollo Hospital, New Delhi, India, Aug 1996 -Dec 1996
7. Medical Oncology / Medicine, Rungta Hospital, Jaipur, India, Feb 1996-Apr 1996
8. Medical Oncology, Tata Cancer Hospital, Mumbai, Sept 1994-Jan 1996
9. Lala Lajpat Rai Medical College (LLRM), Meerut, UP, India, July 1992-Aug 1994

EBMT Nuclear Accident Committee (since 2001)
American Society of Clinical Oncology (since 2001)
American Society of Hematology (since 2000)
European School of Medical Oncology (since 2006)
Early Breast Cancer Trialists Collaborative Group (2006, 2010)
Scientific Advisor, International Myeloma Foundation (2002-2006)
Member, Acute Leukaemia Working Party, European Blood and Marrow Transplantation (EBMT) Group (2002-2004)
Chronic Leukaemia Working Party of EBMT (Since 2002)
Multiple Myeloma Working sub-Committee of EBMT (since 2002)
Stem Cell Trialists Collaborative Group (2002-2007)
European Haematology Association (EHA)(since 2001)
International Advisory Panel on Fungus Infections, Pfizer Limited (2001-2005)
United Kingdom Myeloma Forum Clinical Trials committee (2002-2003)
British Medical Association (since 2002)
British Society for Blood and Marrow Transplantation (2001-2004)
Association of Cancer Physicians (since 2002)
Pan-Thames purchasing BMT Consortium

1. Gera M, Gera B (Sirohi B) . Unusual second malignancies in childhood Retinoblastoma: Indian Journal of Medical and Paediatric Oncology: Vol 17 No 1, March 1996 (40-44).
2. Vaidya S, Saika S, Sirohi B, Pai S, Advani S. Avascular necrosis of bone- a complication of aggressive therapy for acute lymphoblastic leukemia- Acta Oncologica, 1998, 37 (2): 175-7.
3. S. Advani, S. Pai, D. Venzon, M. Adde, P. K. Kurkure, C. N. Nair, B. Sirohi, S. D. Banavali, R. Hawaldar, B. B. Kolhatkar, T. Vats, and I. Magrath Acute lymphoblastic leukaemia in India: An analysis of prognostic factors using a single treatment regimen. Ann. Onc., February 1999, 10: 167 - 176.
4. Sirohi, B., Powles, R., Mehta, J., Raje, N., Kulkarni, S., Ramiah, V., Saso, R., Horton, C., Bhagwati, N., Singhal, S., Treleaven, J. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. British Journal of Haematology 1999, 107: 656-666
5. Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Pandha, H., Bhagwati, N., Horton, C., Singhal, S., Mehta, J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplantation 2000, 25, (5) 533-539
6. Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Sirohi, B., Millar, B., Shepherd, V., Saso, R., Rowland, A., Long, S., Cabral, S., Horton, C., Mehta, J. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow versus blood stem cell transplantation. Bone Marrow Transplantation 2000 25: (5) 501-505.
7. Kulkarni, S., Powles, R., Treleaven, J., Riley, U., Singhal, S., Horton, C., Sirohi, B., Bhagwati, N., Meller, S., Saso, R., Mehta, J. Chronic GVHD is associated with long-term risk of pneumococcal infections in bone marrow transplant patients. Blood, 2000, 95:(12) p3683-86.
8. Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Horton, C., Sirohi, B., Bhagwati, N., Tait, D., Saso, R., Killick, Pinkerton, R., Atra, A., Meller, S., Mehta, J. Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. Bone Marrow Transplant 2000 25,(4) 365-370.
9. Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Raje, J., Horton, C., Singhal, S., Mehta, J., Treleaven, J. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - A phase I/II feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000 25: (9) 949-956.
10. Powles, R., Mehta, J., Kulkarni, S., Treleaven, J., Millar, B., Shepherd, V., Rowland, A., Sirohi, B., Tait, D., Horton, C., Long, S., Singhal, S. Allogeneic blood and marrow stem cell transplantation in haematologic malignant disease: a randomised trial. Lancet 2000, 355: 1231-1237
11. Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Sirohi, B., Horton, C., Millar, J., Shepherd, V., Tait, D., Saso, R., Rowland, A., Long, S., Mehta, J. A low CD34+ cell dose results in higher mortality and poorer survival or marrow stem cell transplantation from HLA-identical siblings: Should CD34+ cells/kg be considered the maximum threshold? Bone Marrow Transplantation, 2000 Sep, 36(5) p489-96.
12. Sirohi B, Powles R L, Kulkani S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, and Treleaven J. Glomerular filtration rate prior to high dose melphalan 200 mg/m2 as a surrogate marker or outcome in patients with myeloma. British Journal of Cancer 2001; 85 (3):325-332.
13. Sirohi, B., and Powles, R., : High-Dose Therapy in Patients with Multiple Myeloma: Oncology Spectrums,2002, 2 (2): Pages 86-95.
14. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplantation, 2001, 28:29-37.
15. Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden Experience. Seminars in Hematology. Vol. 38. July 2001, page 209-18.
16. Sirohi B and Powles R. International Myeloma Grand Round. The Lancet Oncology, Vol 2 (9) 2001: 571-579.
17. Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S, Rudin C, Bhagwati N, Horton C, Saso R, Singhal S, Parikh P. The Implication of compromised renal function at presentation in myeloma. Medical Oncology: vol 18(1) 2001: 39-50
18. Singhal, S., Powles, R., Henslee-Downey, P.J., Chiang, K.Y., Treleaven, J., Godder, K., Kulkarni, S., van Rhee, S., Sirohi, B., Pinkerton, C.R., Meller, S., Mehta, J. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refactory acute leukaemia. Bone Marrow Transplantation, 2002, 29(4): 291-295.
19. Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Tait, D., Singhal, S., Mehta, J. The role of post-transplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukaemia. Blood, 2002, 100(5): 1641-1647.
20. Powles, R., Sirohi, B. Kulkarni, S., Treleaven, J., Rudin, C., Sankpal, S., Goyal, S., Horton, C., Millar, B., Saso, R., Singhal, S., Mehta, J. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplantation, 2002, 30, 479-484.
21. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplantation 2002, 30 (10): 673-9.
22. Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Tait, D., Singhal, S. Does donor-recipient ABO-incompatible protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukaemia? Bone Marrow Transplantation 2002, 29 (10): 853-9.
23. Elnenaei MO, Gruszka-Westwood AM, A’Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma, the relevances of TP53, MDM2, and CDKN2A. Haematologica 2003, 88: 529-537.
24. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic haematopoietic stem cell transplantation : activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplantation 2003, 32:165-70.
25. Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukaemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes? Bone Marrow Transplantation 2003, 32:157-64.
26. Singhal S, Henslee-Downey PJ, Polwes R, Chiang KY, godder K, Treleaven J, Kulkarni S, Van Rhee F, Sirohi B, Pinkerton CR, Meller S, Jovanovic B, Mehta J. Haploidentical vs autologous haematopoietic stem cell transplantation in patients with acute leukaemia beyond first remission. Bone Marrow Transplantation 2003, 31:889-95.
27. Sirohi B, Powles R, Treleaven J, Rudin C, Kulkarni S, Frassoni F, Bacigalupo A, Singhal S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B, Horton C, Mehta J. Reassessing autotransplantation for acute myeloid leukaemiain first remission- a matched pair analysis of autologous marrow versus peripheral blodd stem cells. Accepted for publication in Bone Marrow Transplantation. 2003.
28. Brian GM Durie1, Robert A Kyle2,Andrew Belch3, William Bensinger4, Joan Blade5, Mario Boccadoro6, J Anthony Child7, Raymond Comenzo8, Ben Djulbegovic1, Dorotea Fantl9, Gosta Gahrton10, Jean Luc Harousseau11, Vania Hungria12, Douglas Joshua13, Heinz Ludwig14, Jayesh Mehta15, Angelina Rodrique Morales16, Gareth Morgan16, Amara Nouel17, Martin Oken18, Raymond Powles19, David Roodman20 Jesus San Miguel21, Kazuyuki Shimizu22, Seema Singhal15, Bhawna Sirohi19, Peter Sonneveld23, Guido Tricot24 and Brian Van Ness25. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation1. The Hematology Journal (2003) 4, 379-398.
29. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma working Group. British Journal of Haematology 2003, 121:749-757.
30. Bronwen E Shaw, Peggs K, Bird J, Cavenagh J, Hunter A, Madrigal JA, Russell N, Sirohi B, Towlson K, Williams C, Marks D. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. British journal of Haematology 2003,123:886-895.
31. Pearson IC, Sirohi B, Powles R, Treleaven J, Mortimer PS. The prevalence and nature of skin problems in a modern intensive Haemato-Oncology Unit, Hematology. 2004 Oct-Dec, 9(5-6):415-23.
32. B Sirohi , Powes R Multiple Myeloma . Lancet 2004 363: 875-87.
33. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, Miguel JS, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Ness BV. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. J Haematol 2004, 5(3): 285-295.
34. Sirohi B, Powles R, Kulkarni S, Rudin C, Frassoni F, Bacigalupo A, Singhal S, Vaidya S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B, Treleaven J, Horton C, Mehta J. Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow vs peripheral blood stem cells. Bone Marrow Transplant 2004, 33 (12): 1209-14.
35. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004, 33:1107-14.
36. Sirohi B., Powles R., Mehta J., Rudin C, Kulkarni S., Horton C., Saso R, Singhal S. Treleaven J An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant. 2005 May 16, [Epub ahead of print]
37. Gahrton G, Iacobelli S, Apperley J, Bandini G, Bjorkstrand B, Blade J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kroger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D.The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005 Mar, 35(6):609-17.
38. Sirohi, B., Powles R, Rudin C, Singhal, S., Kulkarni, S., Saso R, Horton, C., Mehta, J, Treleaven J. Using the Original Infusional Induction Chemotherapy Again as Salvage Therapy in Myeloma Patients Relapsing After One Autograft. Hematology. 2005 Oct, 10(5):361-4.
39. CL Alvares, FE Davies, C Horton, G Patel, R Powles, B Sirohi, R Zuha, A Gatt, R Saso, JG Treleaven, CE Dearden, MN Potter, ME Ethell, GJ Morgan Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments, accepted Br J Haematology, 2005
40. Sirohi B, Huddart R. The management of poor-prognosis, non-seminomatous germ-cell tumours. Clin Oncol (R Coll Radiol). 2005 Oct, 17(7):543-52.
41. Prescot AP, Dzik-Jurasz AS, Leach MO, Sirohi B, Powles R, Collins DJ.Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia. J Magn Reson Imaging. 2005 Oct, 22(4):541-8.
42. Vaidya SJ, Ortin M, Lopez-Duarte M, Sirohi B, Powles R, Treleaven J, Richard C. Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection. Leuk Lymphoma. 2005 Aug, 46(8):1143-50.
43. Sirohi B, Powles R, Chopra R, Russell N, Byrne JL, Prentice G, Potter M, Koblinger S. Assessment of Maximum Tolerated Dose (MTD) of FK463 in Cancer Patients Undergoing Haematopoetic Stem Cell Transplantation.- Bone Marrow Transplant. 2006 Jul, 38(1):47-51. Epub 2006 May 22.
44. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow Transplantation. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol. 2006 Aug, 134(4):385-90. Epub 2006 Jul 5
45. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006 Jul, 42(11):1671-83. Epub 2006 Jul 25.
46. Gorin NC, Fliedner TM, Gourmelon P, Ganser A, Meineke V, Sirohi B, Powles R, Apperley J. Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol. 2006 Oct, 85(10):671-9. Epub 2006 Aug 1.
47. Sirohi B, Powles R, Morgan G, Treleaven J, Kulkarni S, Horton C, Saso R, Rolfe D, Cook G, Shaw C, Wass J. Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study. Bone Marrow Transplant. 2007 Jan, 39(2):115-20. Epub 2006 Dec 4.
48. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol Dec 12 [Epub ahead of print]
49. Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica. 2007 Feb, 92(2):271-2.
50. Sirohi B, Powles, R, Oakervee H., Singhal S., Bishop L., Horton C., Kulkarni S., Barnett M., Dyer P., Rintala T., Mehta J, Cavenagh J.D. Upfront Collection of Peripheral Blood Stem Cells (PBSC) in New Patients with Myeloma Receiving Minimal or No Prior Cytoreductive Therapy: Comparison of Two Regimes from Royal Marsden Hospital and St. Bartholomew's Hospital. – Haematology 2007 Apr, 12(2):113-5.
51. Sirohi B, Powles R, Lawrence D., Kulkarni S., Hollis H., Heming D., Sankpal S., Patel G., Singhal S., Treleaven J. Mehta J. An Open, Randomized, Controlled, Phase II, Single Centre, Two-Period Cross Over Study To Compare the Quality of Life (QoL) and Toxicity Experienced on PEG Interferon (P-IFN) with Interferon-a2b (IFN) in Patients with Multiple Myeloma (MM) Maintained on a Steady Dose of IFN- Annals of Oncology 2007 Aug, 18(8):1388-94.
52. Sirohi, B Cunningham D, Norman A, Last K, Chau I, Horwich A, Oates J, Chong G, Wotherspoon A. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).Hematology. 2007 Apr, 12(2):149-53.
53. Murphy F, Sirohi B, Cunningham D. Autotransplantation in Hodgkin Lymphoma. Expert Rev Cancer Therapy. 2007 Mar, 7(3):297-306.
54. Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007 Apr 23, 96(8):1178-82
55. Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, Priest K,O’Brien M Early response to platinum-based first line chemotherapy in non small cell lung cancer (NSCLC) may predict survival. Journal of Thoracic Oncology 2007 Aug, 2(8):735-40.
56. Sirohi, B, Powles R, Harousseau JL, Anderson KC. The evolving background for high-dose treatment for myeloma. Bone Marrow Transplant 2007; Dec, 40(12):1097-100.
57. Sirohi, B, Powles R. Future Challenges. Bone Marrow Transplant 2007; Dec, 40(12):1057-64.
58. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A. Long-term outcome of autologous stem cell transplantation in relapsed or refractory Hodgkin Lymphoma. Ann Oncol 2008 Jul, 19(7):1312-9. Epub 2008 Mar 19
59. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J. The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant. 2008 Jul, 42(2):105-12. Epub 2008 Apr 14.
60. Fliedner TM, Powles R, Sirohi B, Niederwieser D; European Group for Blood and Marrow Transplantation (EBMT) Nuclear Accident Committee (NAC). Radiologic and nuclear events: the METREPOL severity of effect grading system. Blood. 2008 Jun 15, 111(12):5757-8, author reply 5758-9.
61. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008 Nov, 19(11):1847-52. Epub 2008 Jun 20 .
62. Sirohi B, Leary A, Johnston S. Ipsilateral Breast tumour recurrence: current practice and recommendations. The Breast Journal, 2008
63. Cunningham DC, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RTT, Tabah-Fisch T, and Cassidy J.Two Different First-line 5-Fluorouracil Regimens With or Without Oxaliplatin in Advanced Colorectal Cancer (LIFE) : Annals of oncology Oct 14 2008:e-published
64. Sirohi B, Powles R, Singhal S, Smith K, Jones RL, Saso R, Kulkarni S, Treleaven J, Swansbury GJ, Potter M, Morgan G, Mehta J et al. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia. Leuk Lymphoma. 2008 Dec, 49(12):2284-90.
65. Fliedner TM, Chao NJ, Bader JL, Boettger A, Case C Jr, Chute J, Confer DL, Ganser A, Gorin N-C, Gourmelon P, Graessle DH, Krawisz R, Meineke V, Niederwieser D, Port M, Powles R, Sirohi B, Weinstock DM, Wiley A, Coleman CN. Multi-organ Failure in Radiation Emergency Medical Preparedness: A US/European Consultation Workshop. Stem Cells e-published Jan 22, 2009. Stem Cells. 2009 May, 27(5):1205-11
66. Sirohi, B, Powles R. Lenalidomide in Multiple Myeloma, Expert reviews anticancer therapy. Nov 2009, 9(11):1159-1570.
67. Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P. Angiogenesis in cutaneous malignant melanoma and therapeutic strategies. Expert reviews anticancer therapy. Nov 2009, 9(11):1583-1598.
68. Sirohi, B et al A randomised comparative trial of infusional ECisF (epirubicin, cisplatin and infusional 5FU) vs conventional FEC (5FU, epirubicin and cyclophosphamide) as adjuvant chemotherapy in early breast cancer : The TRAFIC(TRial of Adjuvant 5FU Infusional Chemotherapy) trial , Annals of Oncology 2010, Jan
69. Powles R, Sirohi B, Niederwieser D.The role of the European haematologist in a large irradiation emergency: the European Blood and Marrow Transplantation Society (EBMT) Nuclear Accident Committee (NAC). Health Physics 2010 98(6): 810-4.
70. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A.Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experienceAnnals Oncology 2010, Mar 23- epub
71. Noble J, Sirohi B, Ashley S, Ladas G, Smith I.Sternal/para-sternal resection for parasternal local recurrence in breast cancer.Breast 2010, Mar –epub

1. Burkitts Lymphoma - A TMH experience at XXXVI Annual Conference of ISHBT (Indian Society of Haematology and Blood Transfusion) 1995, Bangalore.
2. CNS directed chemotherapy in children less than or equal to 3 years of age: Use of G-CSF in maintaining dose intensity- in Feb 1997 at Madurai in ISMPO (Indian Society of Medical and Paediatric Oncology).
3. Low incidence of cardio toxicity following daunomycin and doxorubicin at a 10 year follow-up in March 1997 at Annual Conference of Bombay Haematology group at Bombay
4. Single centre evaluation of long term follow up of autologous stem cell transplantation for first remission adult ALL: potential for cure without excessive toxicity; Annual meeting of European Bone Marrow Transplantation (EBMT) Group, Innsbruck 6th March 2000.
5. Central nervous system relapse after stem cell transplantation (SCT) for acute leukaemia beyond first remission, Annual meeting of EBMT Group, Innsbruck 6th March, 2000.
6. CNS relapse after auto- and allo- stem cell transplant (SCT) for acute leukaemia beyond first CR. 5th Annual Meeting of the European Haematology Association, June 2000.
7. High-dose mephalan with auto-transplantation in Myeloma patients with severe renal dysfunction (GFR <20 ML/MIN/Ms): High incidence of atrial fibrillation and treatment related mortality. 6th Congress of European Haematology Association (EHA) Frankfurt, 24 June 2001
8. Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. 28th EBMT Annual Meeting, Montreux, Switzerland, 25th March 2002
9. Bone marrow or peripheral blood stem cell auto transplantation (PBSCT) for acute myeloid leukaemia in first remission? A matched-pair analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant group (EBMT). 28th EBMT Annual Meeting, Montreux, Switzerland. 27th March 2002
10. Salvage autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. Annual Scientific Meeting of the British Society for Haematology, Brighton, UK. 16th April, 2002.
11. Single centre results of 200mg/m2 melphalan (HDM200) and autograft (tx) in 451 myeloma patients: identifying patients with prolonged survival based upon albumin and 2 Microglobulin at transplant at American society of clinical Oncology, Orlando, 20th May 2002
12. Outcome of auto transplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy: 7th Congress of European Haematology Association (EHA), Florence, and Itlay.9th June 2002.
13. High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem auto transplantation. 7th Congress of EHA, Florence, Italy, 7th June 2002.
14. Long-Term Outcome of Myeloma Patients Treated with an Elective Single Autograft with Follow-up (5 Years): Results Comparable to Tandem Auto transplantation, American society of Haematology, Philadelphia, 9th Dec 2002.
15. Prognostic Factors at the Time of Single Auto transplantation in 451 Myeloma Patients treated with 200 mg/m2 Melphalan: Results Equivalent to Tandem Auto transplantation, American society of Haematology, Philadelphia, and 9th December 2002.
16. Auto transplantation in Myeloma: Prognostic factors, 29th EBMT Annual Meeting, Istanbul, Turkey, 21st July 2003
17. Prognostic factors at the time of auto transplantation in myeloma ,8th Congress of EHA, Lyons, France 14th June 2003
18. Results of randomised, cross over study comparing pegylated interferon with interferon-alpha2b in patients with myeloma, 8th Congress of EHA, Lyons, France 15th June 2003
19. Serum free light chain assessment in myeloma patients in complete remission, 29th EBMT Annual Meeting, Istanbul, Turkey, 21st July 2003
20. Randomised, two-period cross over study comparing quality of life and toxicity of pegylated interferon with interferon-alpha2b in patients with myeloma, 29th EBMT Annual Meeting, Istanbul, Turkey, 22nd July 2003.
21. Effect of human growth hormone in haemato-oncology patients receiving intensive chemotherapy- a double-blind randomised placebo controlled trial , 23rd joint meeting of British Endocrine societies , Brighton, 23rd March 2004.
22. Long term use of Capecitabine in patients with locally recurrent or metastatic breast cancer: concept for metronomic chemotherapy, ESMO Lugano 2008